INTRODUCTION
Bile acids, in addition to their role in the emulsification of dietary lipids (Borgstrom et al., 1985) , have been recognized as important signaling molecules and physiological ligands for several nuclear receptors (Chiang, 2002) . The nuclear receptors that have been recognized as being involved in the regulation of biosynthesis, metabolism, and transport of bile acids, are the human farnesoid orphan receptor (hFXR), the liver X receptor, the peroxisome proliferator-activated receptors (PPARs), the human pregnane orphan receptor (hPXR) (Chiang, 2002) , and the human vitamin D receptor (hVDR) (Makishima et al., 2002) . hFXR is the major bile acid receptor and primary bile acids are its physiological ligands (Takeshita et al., 2002) .
Growing evidence has been collected that bile acids are strongly involved in the regulation of their own synthesis and transport, as well as cholesterol homeostasis and lipid metabolism. It has been shown that bile acids activate hFXR, which regulates several target genes, including drug metabolizing enzymes. Several examples of gene regulation via bile acid activation of nuclear receptors include cytochrome P450 7A1, which has been identified as a target gene of the bile acid-specific receptor, hFXR (Russell and Setchell, 1992) . hFXR negatively regulates bile acid synthesis by decreasing transcription of cytochrome P450 7A1 and cholesterol 12α-hydroxylase, the enzyme responsible for cholic acid synthesis, is also under negative control by bile acids (Vlahcevic et al., 2000) . In addition, hFXR activates transcription of ileal-bile acid binding protein (I-BABP), which is involved in the enterohepatic circulation of bile acid (Princen et al., 1997) . Moreover, hFXR mediates bile acid activation of phospholipid transfer protein gene expression (Urizar et al., 2000) , which suggests that bile acids and hFXR my play a role in high-density lipoprotein metabolism via the regulation of this gene. Several more bile acid transporters, including organic anion transport protein 2 (OATP2) and the DMD #3061 5 bile salt export pump, which promotes bile acid efflux from the liver (Bjorkhem, 1985) , have been recognized as hFXR target genes activated by bile acids (Ananthanarayanan et al., 2001) .
It has been shown that hFXR also controls the metabolism of triglycerides. bile acid-activated hFXR suppresses apolipoprotein A-I and apolipoprotein C-III transcription Claudel et al., 2002) . It was shown that the suppression of apolipoprotein A-I occurs via a novel negative hFXR response element (NFRE) (Claudel et al., 2002) . Also, enzymes involved in bile acid detoxification, especially of lithocholic acid, have been identified as being under the control of bile acid-mediated regulation. Very recently, direct involvement of hFXR in the regulation of human UDP-glucuronosyltransferase (UGT) 2B4 has been demonstrated in human primary hepatocyte cultures (Barbier et al., 2003b) .
Recent findings indicate that three additional nuclear receptors, PXR, PPARα and hVDR, accept bile acids as ligands and regulate bile acid synthesis and transport. It has been demonstrated that PPARα may modulate metabolic pathways common to hFXR. The first molecular evidence for cross-talk between hFXR and PPARα pathways in humans has been found (Torra et al., 2003) . Bile acid-mediated activation of PXR has been postulated in the regulation of multidrug resistance-associated protein 3 (Mrp3) (Staudinger et al., 2003) and has been shown to regulate cytochrome P450 3A4 expression (Takeshita et al., 2002) . Bile acids seem to be involved in the regulation of several biologically important metabolic pathways by the induction and/or suppression of hFXR, PPARα, and PXR target genes. hVDR is also activated by bile acids (Makishima et al. 2003) . It has been demonstrated that lithocholic acid is a higher affinity ligand for hVDR than for either hFXR or PXR. The identification of hVDR as an intestinal bile acid sensor may indicate an additional mechanism for the protective effects of vitamin D and its receptor against toxic lithocholic acid. It has DMD #3061 6 been demonstrated that activation of hVDR by lithocholic acid or vitamin D induces expression in vivo of cytochrome P450 3A enzymes that detoxifies lithocholic acid in the liver and intestine.
Bile acids have been identified as excellent substrates for human UGTs (Gall et al., 1999) . UGTs are phase II biotransformation enzymes localized to the endoplasmic reticulum (Chowdhury et al., 1985) that catalyze the conjugation of glucuronic acid to a broad spectrum of endobiotic and xenobiotic substrates with diverse chemical structures. Endogenous substrates for UGTs include bilirubin, bile acids, fatty acids, prostaglandins, serotonin, thyroid hormones, biogenic amines and steroid hormones . Additionally, UGTs have a large number of xenobiotic substrates, including fat-soluble vitamins, carcinogens, plant metabolites, environmental pollutants, and drugs such as acetaminophen, chloramphenicol, diethylstilbestrol, morphine, and salicylic acid (Burchell et al., 1998; Radominska-Pandya et al., 1999; Tukey and Strassburg, 2000) . UGT2B7 is one of two major human isoform involved in the glucuronidation of both the hydroxyl and carboxyl functions of bile acids.
In this work, we have identified the gene encoding human UGT2B7 as a new target of lithocholic acid-mediated suppression. The transcription of UGT2B7 is down-regulated by lithocholic acid, and we have collected reliable evidence that hFXR is involved in this process. This down-regulation could result in a dramatic accumulation of toxic lithocholic acid in cells and the development of severe cholestasis. It is anticipated that identification of the mechanism of lithocholic acid toxicity will result in the successful development of drugs that will prevent cholestasis and other lithocholic acid-mediated toxicities. (ATCC HB-8065) and human colorectal adenocarcinoma cells line, Caco-2 (ATCC HTB-37), were obtained from the American Type Culture Collection (Manassas, VA). Both cell lines were maintained at 37ºC, 5% CO 2 in high glucose Dulbecco's Modified Eagle Medium (DMEM) with Earle's salts and L-glutamine (Invitrogen, Carlsbad, CA), supplemented with 1% non-essential amino acids, 1mM sodium pyruvate and 10% fetal bovine serum (Invitrogen). The culture medium was changed twice weekly during maintenance and untransfected cells used for RNA isolation were harvested when they neared confluence. In experiments with transcription inhibitor, 1 µg/ml of actinomycin-D was added to the culture medium together with vehicle or lithocholic acid, and mRNA was collected at various time points, as shown in the figure.
For transient transfection, HepG2 or Caco-2 cells were seeded in 6-well plates at 1x10 6 and 2.5x10 For each primer pair, we performed PCR with different cycle numbers and plotted these data to form a standard curve. We chose the cycle that was found to be within the non-saturable range of amplification for use in further experiments. All other conditions were kept consistent unless significant changes in mRNA level were observed.
Real-time PCR assay -Real-time PCR analyses were performed with lithocholic acid-treated Caco-2 cells for comparison with the data obtained from semi-quantitative PCR. Real-time PCR primer sequences for UGT2B7 and GAPDH were obtained from Congiu (Congiu et al., 2002) and Knerr (Knerr et al., 2002) , respectively.
Inhibition of UGT2B7 transcription in the presence of varying concentrations of lithocholic acid was evaluated by real-time RT-PCR and used to find the IC 50 value, which was determined using Prisim4 software (GraphPad, San Diego, CA). The real-time PCR reaction mixture contained 5 µ l of the sample and 20 µ l of a master mix containing forward and reverse primers (300 nM each), IQ SYBR Green Supermix (2x, Bio-Rad, Hercules, CA) and the appropriate volume of sterile water. PCR DMD #3061 10 conditions were 3 min at 95°C, followed by 40 cycles of 95 °c for 10 s and 60°C for 45 s. Optical data were collected during the 60 °C step. PCR reactions were carried out in 96-well thin-wall PCR plates covered with optically clear sealing film (Bio-Rad). Amplification, detection and data analysis were performed with an iCycler IQ real-time detection system (Bio-Rad).
A standard curve was generated from a cDNA dilution series (1 ng, 5 ng, 25 ng) constructed as reference samples from the DMSO control sample. Real-time PCR of UGT2B7, I-BABP and GAPDH were performed in duplicate on both the experimental cDNA samples (10 ng) and reference standards.
Values for target abundance in each experimental sample were extrapolated from the standard curve generated with the reference standards. The final data were expressed as the ratio of the values for the genes of interest and the corresponding values for GAPDH.
Isolation of UGT2B7 promoter fragments -Clones containing UGT2B7 promoters were isolated from a human placenta lambda genomic library (Clontech, Palo Alto, CA) after several rounds of screening. Briefly, DNA fragments from the 5'-ends of cDNAs encoding the UGTs of interest were labeled with 32 P-dATP by random priming using the DECAprime II DNA labeling kit (Ambion, Austin, TX). Hybond-N membranes (Amersham Biosciences, Piscataway, NJ) from plaque lifts were denatured, neutralized and UV cross-linked according to the manufacturer's protocol (PT1010-1).
Pre-hybridization was carried out in a solution of 5x SSC (0.375 M NaCl, 0.0375 M sodium citrate), 5x
Denhardt's (Ficoll, polyvinylpyrrolidone, and BSA, 1 mg/ml each) and 0.5% SDS for 4 hours at 42°C before hybridization with 1 x 10 6 cpm/µl of probe overnight. Membranes were washed twice in 2x SSC, 0.1% SDS for 5 minutes at room temperature, and twice in 0.1x SSC, 0.1% SDS for 30 minutes at 65°C
followed by exposure to autoradiography film with intensification screens at -70°C overnight. Positive plaques were picked and screened by restriction digestion and sequencing for appropriate UGT DMD #3061 11 promoter inserts. A UGT2B7 1.3 kb proximal promoter was amplified from these clones by PCR, using primers designed with information from the sequencing of the genomic clones and/or from the human genome databases. The primers contained Kpn1 and Mlu1 sites for directional cloning into the KpnI and MluI sites of the pGL3-Basic luciferase reporter vector (Promega, Madison, WI).
Generation of the UGT2B7 promoter-luciferase reporter constructs -A series of 5' deletion
constructs containing different promoter fragments were generated from the 1.3 kb proximal UGT2B7
promoter construct [2B7(p1328)] using the Erase-a-Base  system (Promega). The plasmid containing the insertion was double-digested by MluI and KpnI. The linear fragment was further digested by
Exonuclease III and aliquots were removed at different times to obtain a series of 5'-deletions. S1
nuclease was added to remove the remaining 5'-overhang and the resulting blunt ends were linked by adding Klenow fragment, dNTPs and T4 DNA ligase. Plasmids were transformed into the E.coli DH10B strain and incubated at 37°C overnight. Positive clones containing the UGT2B7 promoter were verified by direct DNA sequencing.
Deletions and site-directed mutagenesis -For deletion of the NFRE sequence in 2B7(p1328)-Luc to create 2B7(p1315)NFRE∆-Luc, two oligonucleotides were designed by Oligo Lite software and synthesized by Integrated DNA Technologies (Coralville, IA):
The NFRE was in the middle of the oligonucleotides with 16 bases of correct sequence on either side.
Constructs with deletions within the NFRE, 2B7(p1328)mut-Luc and 2B7(p428)mut-Luc, were prepared using the following primers: Sense and antisense strands of the same element were annealed by heating at 65°C for 10 minutes and cooling to room temperature. Double strand probes were labeled by γ-[ An IC 50 value of 13.7 µM for lithocholic acid-mediated inhibition of UGT2B7 mRNA expression was calculated from these real-time RT-PCR experiments.
To test the response of UGT2B7 gene expression to other, non-toxic bile acids, hyodeoxycholic
acid and ursodeoxycholic acid were tested in Caco-2 cells, and RT-PCR showed that neither hyodeoxycholic acid nor ursodeoxycholic acid induced or suppressed UGT2B7 mRNA levels (data not shown). Experiments carried out with HepG2 cells showed that neither lithocholic acid nor chenodeoxycholic acid, up to a concentration of 75 µM, affected UGT2B7 mRNA levels (data not shown). The lack of effect of chenodeoxycholic acid on UGT2B7 mRNA in HepG2 cells was in an agreement with recently published data by (Barbier et al., 2003a) .
In the next series of experiments, we investigated and compared the effect of lithocholic acid and chenodeoxycholic acid on I-BABP expression. We selected I-BABP because it was the first gene DMD #3061
15
identified as a target of chenodeoxycholic acid-activated hFXR, representing hFXR-mediated induction (Grober et al., 1999) . As shown in Figure 1C , lithocholic acid acted as an activator of I-BABP expression up to a concentration of 10 µM, but at 20 µM, mRNA levels began to decrease and by 30 µM, mRNA expression had returned to basal levels. In contrast, chenodeoxycholic acid showed a strong activating effect on I-BABP up to 75 µM (Fig. 1D ), in agreement with previous reports (Grober et al., 1999) . These experiments with I-BABP confirmed that both lithocholic acid and chenodeoxycholic acid up-regulate the expression of I-BABP genes. Strong negative regulation by bile acids, especially lithocholic acid, was observed exclusively with UGT2B7. Moreover UGT2B7 was also more sensitive to the higher concentrations of chenodeoxycholic acid. The direct comparison of the effect of chenodeoxycholic acid on UGT2B7 and I-BABP can be seen in Figure 1B and D. The experiments with I-BABP serve as important positive controls for our studies with lithocholic acid and chenodeoxycholic acid, proving that the effects of these two ligands are in fact gene dependant.
To exclude the possibility that toxic lithocholic acid affects the integrity of Caco-2 cells, we checked their viability by Trypan Blue staining. All concentrations of lithocholic acid, including those that significantly decreased UGT2B7 mRNA expression, were found to be well tolerated by the cells, and no obvious cytotoxicity was observed. (Data not shown).
Finally, to assure that UGT2B7 mRNA suppression was not due to increased instability of mRNA in the presence of lithocholic acid, we used actinomycin-D, an inhibitor of transcription, to evaluate the stability of UGT2B7 mRNA in the presence of lithocholic acid. As shown in Figure 2 , the half-life of have been proven to be PXR target genes, were induced by rifampicin (Rif) treatment. Since lithocholic acid is also a ligand for PXR (Xie et al., 2001 ), we investigated whether UGT2B7 is also a target gene of PXR. To eliminate the possibility that negative regulation of UGT2B7 by lithocholic acid could be mediated via PXR, Caco-2 cells were treated with Rif, a PXR-specific ligand (Kliewer and Willson, 2002) , and it was demonstrated that Rif had no effect on UGT2B7 transcription (data not shown). In HepG2 cells, Rif did not change UGT2B7 mRNA expression. Additional experiments involving the transfection of Caco-2 cells with activated PXR in the presence and absence of lithocholic acid, and it was demonstrated that PXR transfection had no effect on UGT2B7 transcription (data not shown). The outcome of both sets of experiments suggests that PXR is not involved in UGT2B7 down regulation.
The effect of chenodeoxycholic acid and lithocholic acid on the 1.3 kb UGT2B7 promoter fragment
-In the first series of experiments, we compared the effects of lithocholic acid and chenodeoxycholic acid on the 1.3 kb UGT2B7 promoter construct in Caco-2 cells co-transfected with hFXR and/or hRXR (Fig 3) . As observed previously, hFXR co-transfected into Caco-2 cells with 2B7(p1328)-Luc caused a decrease in luciferase activity even in the absence of ligand, and co transfection with hRXR additionally decreased the luciferase activity. However, the two bile acids had different effects on luciferase activity in these co-transfected cells. In the absence of receptors, 25 µM chenodeoxycholic acid did not suppress the luciferase activity, whereas 15 µM lithocholic acid resulted in a suppression of approximately 50%. In cells co-transfected with hFXR and then exposed to ligand, additional suppression was observed in cells exposed to lithocholic acid, but chenodeoxycholic acid seemingly protected the cells from some or all of the suppressive effects of hFXR and hRXR on luciferase activity.
Mapping of an hFXR response element in the human UGT2B7 promoter -We next investigated
whether the observed lithocholic acid-mediated changes in UGT2B7 gene expression were the due to response elements located in the gene promoter. To localize the region within the UGT2B7 promoter that contains transcriptional responsiveness to lithocholic acid, serial deletion constructs of the promoter, from 2B7(p1328)-Luc to 2B7(p428)-Luc, were generated, cloned in the pGL3-luciferase reporter plasmid, and transfected into Caco-2 cells, which were then treated with lithocholic acid (Fig.   4A ). A significant decrease in reporter activity in response to lithocholic acid was observed for each deletion constructs except p-128, indicating that the region controlling the suppressive effect of lithocholic acid on the UGT2B7 promoter was between -428 bp and -128 bp.
To further demonstrate that the -428 to -128 bp region of the UGT2B7 promoter was responsible for the hFXR-mediated lithocholic acid suppression, we measured the effect of lithocholic acid treatment and co-transfection with hFXR and/or hRXR on these promoter constructs. Caco-2 cells were transfected with the luciferase reporter plasmids driven by these constructs and co-transfected with the expression vectors for hFXR and hRXR in the presence and absence of lithocholic acid (Fig 4B) . While the activity of the -428 bp promoter was suppressed by lithocholic acid, hFXR, and hRXR, this effect was completely abolished in the -128 bp promoter fragment. These results demonstrate the importance of the region between -428 to -128 bp in the regulation of the UGT2B7 promoter.
Identification and mutation of a NFRE in the -428 to -128 promoter region -Computer analysis of
the -428 to -128 bp region of the UGT2B7 promoter revealed the presence of a GATCCTTGATATTA sequence between nucleotides -148 to -134, which resembles the NFRE, 3'-GATCCTTGAACTCT-5', DMD #3061 18 previously identified in apolipoprotein A-I (Claudel et al., 2002) . To determine whether this sequence could be a NFRE, this 14 bp region was deleted from the 1.3 kb promoter luciferase construct, resulting in the 2B7(p1315)NFRE∆-Luc construct. We also mutated this response element in the luciferase construct to create 2B7(p1329)mut-Luc. Both of these new constructs were then analyzed for lithocholic acid suppression, and compared to that of 2B7(p1328)-Luc. As shown in Figure 5 , these mutations abolished the suppression of UGT2B7 promoter activity by hFXR and hRXR. However, the effect of lithocholic acid alone was not completely reversed. Two conclusions can be drawn from these data. First, deletion of the NFRE eliminates the suppression of UGT2B7 mRNA by hFXR and hRXR suggesting that this is a true NFRE. Second, lithocholic acid suppression of UGT2B7 mRNA is only partially related to the presence of this NFRE; thus, a significant portion of the suppression is the result of another signaling pathway.
EMSA -Suppressive regulation of UGT2B7 by the NFRE indicated that this motif might be a binding site for hFXR. Binding of the hFXR complex to the NFRE in the UGT2B7 promoter was examined by EMSA (Fig. 6) . As a control, a known NFRE from apolipoprotein A-I was also used as a probe. When nuclear extract prepared from Caco-2 cells treated with lithocholic acid was incubated with a 32 P-labeled UGT2B7-NFRE probe, induced DNA-protein complexes were detected (Fig. 6A) .
Binding of hFXR was inhibited in a concentration dependent manner by increasing concentrations of unlabeled oligonucleotides. A similar experiment was done with a 32 P-labeled IR-1 probe (Fig. 6B) .
Competition for the labeled probe was observed when a 50-fold excess of unlabeled IR-1, UGT2B7-NFRE, or apolipoprotein A-I-NFRE was included in the reaction. In order to eliminate unspecific binding, experiments were done using mutated IR-1 and CREB oligonucleotides as non-specific inhibitors (Fig. 6C) . In contrast to the IR-1 and UGT2B7-NFRE probes, binding of the negatively regulated target gene of hFXR. This is in contrast to the bile acid-activated hFXR suppression of apolipoprotein A-I transcription mediated by a similar NFRE, but in a manner independent of hRXR (Claudel et al., 2002) . Recently, it has been reported that another human UGT isoform, UGT2B4, is a target gene for hFXR and induction of this UGT increases bile acid glucuronidation in HepG2 cells (Barbier et al., 2003) . In this case, hFXR binds as a monomer to the BARE in the UGT2B4 gene promoter. In addition, activation of hRXR represses the UGT2B4 gene expression induced by chenodeoxycholic acid and over-expression of UGT2B4 in HepG2 cells results in reduced hFXR-mediated induction of the short heterodimeric partner.
Our results reveal that, in Caco-2 cells, lithocholic acid dramatically decreased expression of UGT2B7 mRNA levels (Figs. 1) and also decreased the luciferase activity of the UGT2B7 promoter. In contrast, this effect was not observed in HepG2 cells. We carried out a series of experiments to examine the effect of transfection of hFXR on UGT2B7 mRNA expression in Caco-2 cells. Transfection of cells with hFXR resulted in a very significant suppression of UGT2B7 expression in the absence of lithocholic acid and additional suppression was observed when the cells were treated with lithocholic acid. The observation that hFXR, and hFXR/hRXR suppress UGT2B7 transcription in the absence of DMD #3061 21 ligand is not surprising. Many orphan receptors, such as human liver X receptor, are able to stimulate gene transcription without ligand binding (Peet et al., 1998) . Another example has been presented for cytochromes P450 where, without bile acid activation, hFXR binds and stimulates rat cytochrome P450 7A1 mRNA expression in HepG2 cells; on the other hand, in the absence of hFXR, bile acids suppress the transcription of the cytochrome P450 7A1 gene (Chiang et al., 2000) . Our data demonstrate that hFXR can act as a UGT2B7 transcriptional suppressor either when overexpressed and presumably unliganded as well as in the presence of one of its natural ligands, lithocholic acid.
hFXR may compete with other nuclear receptors for limiting co-activators, such as steroid receptor coactivator-1. For example, hepatic nuclear factor 4 (HNF 4 ) binds to the direct repeat (DR)-1 motif in BARE-II and plays a role in the transactivation of cytochrome P450 7A1 transcription (Crestani et al., 1998) . Evidence has also been presented showing that the suppression of apolipoprotein A-I by bile acid, mediated by hFXR, is carried out in a manner independent of the SHP regulatory pathway, but via a NFRE (Claudel et al., 2002) . It has been documented that PXR is a bile acid receptor that plays a critical role in bile acid detoxification by the liver; specifically, lithocholic acid has been identified as a PXR activator ligand (Xie et al., 2001) . In the present studies, we found no evidence that lithocholic acid activation of PXR suppresses the transcription of UGT2B7. Specifically, the PXR specific ligand, Rif, had no effect on the repression of UGT2B7 transcription in Caco-2 cells, indicating that PXR is not involved in this phenomenon. The exclusion of SHP and PXR involvement suggests that the down-regulation of UGT2B7 by lithocholic acid is mediated though the supressor activity of hFXR.
In order to understand the mechanism of this negative regulation, we cloned a 1.3 kb fragment of UGT2B7 promoter and carried out deletion analysis in order to identify the region of the promoter involved in the repression of UGT2B7 transcription. Promoter deletion identified a promoter fragment hFXR/hRXR heterodimers bind to these specific DNA motifs. However, hFXR/hRXR can also bind to direct repeats of the AGGTCA hexamer separated by 0, 3, or 4, nucleotides (Laffitte et al., 2000) .
Moreover, hFXR also binds as a monomer to a negative regulation site in the apolipoprotein A-1 gene promoter (Claudel et al., 2002) . In this study, we have demonstrated that hFXR can bind to the slightly modified NFRE in the human UGT2B7 promoter in a manner similar to that described for the apolipoprotein A-1 promoter Mutations of this element in the UGT2B7 -1328 bp promoter fragment abolished the repression of UGT2B7 promoter activity by hFXR and/or hRXR, indicating an absolute requirement of this fragment for the hFXR-induced repression.
The physiological role of the UGT2B7 suppressive regulation pathway remains to be clearly delineated. We have demonstrated experimentally that cholestatic lithocholic acid is converted to the hydrophilic hyodeoxycholic acid in a reaction catalyzed by cytochrome P450 3A4 Xie et al., 2001) . Since, in humans, hyodeoxycholic acid-6-0-glucuronide, rather than hyodeoxycholic acid itself, is excreted in bile and urine, we postulated that coupling between cytochrome P450 3A4 and UGT2B7 occurs as an indispensable pathway for lithocholic acid detoxification Zimniak et al., 1991) . We have also demonstrated that, in rats, lithocholic acid can be directly glucuronidated at the 3-OH position, forming the 3-O-glucuronide of lithocholic acid one of the most cholestatic compounds identified thus far (Oelberg et al., 1984) . The sequential detoxification of lithocholic acid by cytochrome P450 3A4 and UGT2B7 is highly specific to DMD #3061 23 humans.
We propose the pathway depicted in Figure 12 as a putative mechanism for hFXR/PXR-mediated bile acid regulation of the transcription of several genes involved in the synthesis and detoxification of lithocholic acid. In this figure, lithocholic acid is produced from chenodeoxycholic acid by the action of bacterial 7α-dehydroxylase. Subsequently, lithocholic acid is specifically hydroxylated at carbon 6 by cytochrome P450 3A4 and then conjugated at this hydroxyl group to produce a water soluble glucuronide. We have shown previously that the 6-hydroxyl group of hyodeoxycholic acid and both the carboxyl and hydroxyl group of lithocholic acid can be glucuronidated by human UGT2B7 (Gall et al., 1999) .
As presented in Figure 7 , there are three enzymes involved in the biosynthesis (7α-dehydroxylase) and detoxification (cytochrome P450 3A and UGT2B7) of lithocholic acid. Detoxification of lithocholic acid by cytochrome P450 3A4 is up-regulated by activation of cytochrome P450 3A4
expression by lithocholic acid-activated PXR. cytochrome P450 3A4 converts lithocholic acid to hyodeoxycholic acid, which, as a substrate for UGT2B7, is effectively glucuronidated and then excreted in bile and/or urine. Up-regulation of cytochrome P450 3A4 via lithocholic acid is a significant hepatoprotective mechanism. However, we have unexpectedly discovered that UGT2B7, the final enzyme involved in this scheme, is down regulated in Caco-2 cells by the presence of high levels of lithocholic acid. The down regulation of this last enzyme involved in the lithocholic acid detoxification process, could be highly deleterious both in the intestine and the liver.
We would like to emphasize that suppression of UGT2B7 mRNA levels might occur only in high concentrations of lithocholic acid. It has been demonstrated that low, micromolar concentrations of lithocholic acid are effectively cleared via sulfation (Halvorsen et al., 1999; Radominska et al., 1993) ; whereas at high concentrations, glucuronidation takes over the lithocholic acid detoxification process.
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24 Therefore, we postulate that the suppression of UGT2B7 expression might only occur under pathological conditions, such as liver damage and/or cholestasis, which are known to produce significant levels of lithocholic acid.
All this work in contrast to work done by Barbier et al. (Barbier et al., 2003a) 
